Adverts

Open Access Articles- Top Results for WAY-317,538

WAY-317,538

</th></tr>
WAY-317,538
240px
Systematic (IUPAC) name
5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide
Clinical data
  • Legal
Identifiers
 7pxY
ChemSpider 24663034 7pxN
ChEMBL CHEMBL1084615 7pxN
Chemical data
Formula C20H25N3O2
339.430
 14pxN (what is this?)  (verify)

WAY-317,538 (SEN-12333) is a drug that acts as a potent and selective full agonist for the α7 subtype of neural nicotinic acetylcholine receptors. It was not the most potent compound in the series, but was selected for further development on the basis of its high selectivity over related receptors, ease of synthesis, and good in vivo properties including high oral bioavailability and good brain penetration.[1] It has nootropic and neuroprotective effects in animal studies, and is being investigated as a potential treatment for neurodegenerative and neurocognitive conditions including Alzheimer's disease and schizophrenia.[2]

References

  1. ^ Haydar, S.; Ghiron, C.; Bettinetti, L.; Bothmann, H.; Comery, T.; Dunlop, J.; La Rosa, S.; Micco, I.; Pollastrini, M.; Quinn, J.; Roncarati, R.; Scali, C.; Valacchi, M.; Varrone, M.; Zanaletti, R. (2009). "SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist". Bioorganic & Medicinal Chemistry 17 (14): 5247–5258. PMID 19515567. doi:10.1016/j.bmc.2009.05.040.  edit
  2. ^ Roncarati, R.; Scali, C.; Comery, T.; Grauer, S.; Aschmi, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C.; Zanelli, U.; Ghiron, C.; Haydar, S.; Dunlop, J.; Terstappen, G. C. (2009). "Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders". The Journal of Pharmacology and Experimental Therapeutics 329 (2): 459–468. PMID 19223665. doi:10.1124/jpet.108.150094.  edit


Template:Navbox with collapsible sections


Lua error in package.lua at line 80: module 'Module:Buffer' not found.